title: Clinical characteristics, antimicrobial susceptibilities, and outcomes of patients with Chryseobacterium indologenes bacteremia in an intensive care unit.
abstract: Ten patients with intensive care unit (ICU)-acquired Chryseobacterium indologenes  bacteremia between January 2004 and December 2008 were studied. The primary site of infection was  unknown for 80% of the cases. The known primary sites of infection were empyema (10%) and  catheter-related bacteremia (10%). Eight patients (80%) had polymicrobial bacteremia, spent more  than 21 days in the ICU, and received more than 14 days of broad-spectrum antibiotic therapy prior  to the onset of C. indologenes bacteremia. All isolates were 100% susceptible to minocycline and  trimethoprim/sulfamethoxazole. Vancomycin, imipenem, piperacillin/tazobactam, ciprofloxacin, and  levofloxacin exhibited 0%, 10%, 20%, 30%, and 30%, respectively, susceptibility against this  pathogen. All isolates were 100% resistant to ceftazidime, cefepime, meropenem, piperacillin, and  amikacin. The 14-day mortality rate was 40%. Our findings suggest that this pathogen should be  included among the causes of ICU-acquired bacteremia, especially in patients with a prolonged stay  in an ICU or who had received long-term broad-spectrum antibiotic therapy. Extended-spectrum  penicillins, third- and fourth-generation cephalosporins, and quinolones had very little or no  effect against this pathogen. Therefore, choosing an appropriate antibiotic therapy for this  pathogen is very difficult.
authors: Department of Critical Care Medicine, Tainan Municipal Hospital, Tainan, Taiwan. choudw＠gmail.com
authors: Deng-Wei
authors: DW
authors: Chou
authors: Shu-Ling
authors: SL
authors: Wu
authors: Chao-Tai
authors: CT
authors: Lee
authors: Fan-Ting
authors: FT
authors: Tai
authors: Wen-Liang
authors: WL
authors: Yu
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000494:pharmacology; D016470:Bacteremia / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology*; D045247:Chryseobacterium / Q000187:drug effects / Q000302:isolation & purification*; D003428:Cross Infection / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology; D024881:Drug Resistance, Bacterial; D005260:Female; D045826:Flavobacteriaceae Infections / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology*; D006801:Humans; D007362:Intensive Care Units; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents